Qiaoli Wang

DDLS Fellow | Precision Medicine and Diagnostics research

Dr. Qiaoli Wang is an Associated Senior Lecturer (eq. Assistant Professor) at Department of Translational Medicine at Lund University. She received her MD degree and specialization training in Oncology through Sino-French 7-year Medical Education Program in Wuhan University, China, which is cooperated with Université de Lorraine in Nancy, France.

She obtained her PhD degree from Karolinska Institutet in Stockholm, Sweden, and with an exchange study at Harvard T.H. Chan School of Public Health in Boston, US. Dr. Wang then joined Dana-Farber Cancer Institute as a Research Fellow and became a Teaching Fellow and Course Director for MMSCI master program at Harvard Medical School.

In April 2025, she started her own research lab at Lund University as a Data-Driven Life Science Fellow (DDLS) in Precision Medicine and Diagnostics.

Our research

The Integrative Pancreatic Cancer Research (iPanCare) Lab is led by Dr. Qiaoli Wang. The lab aims to advance understanding of pancreatic cancer, with a strong emphasis on precision prevention, diagnostics, and medicine. Applying classical epidemiology, genetic and molecular epidemiology, and machine learning algorithms, we try to dissect the complexities of this lethal disease.

They leverage large population-based cohorts, national registries, biobanks, electronic health records, and clinical imaging to explore the causes, development, and prognosis of pancreatic cancer, as well as to identify markers for early detection.

Aim

Develop personalized strategies for cancer prevention and risk stratification
Enable early detection of pancreatic cancer
Design individualized therapeutic and prognostic tools

Ultimately, the goal is to improve early diagnosis and increase survival rates for pancreatic cancer patients through facilitating personalized screening programs, treatments, and surveillance strategies.

Strengths of the group

The group is privileged with application of interdisciplinary methodology, which combines epidemiology with multi-omics technology and machine learning. Leveraging diverse data sources, the group’s strengths also include advanced data management skills and expertise in sophisticated statistical modelling in large databases.

The Wang team is also a highly dynamic research group with diverse areas of expertise, committed to leveraging state-of-the-art technologies to advance our understanding and bridge critical knowledge gaps in pancreatic cancer.

In addition, they focus on the data-driven precision medicine of pancreatic cancer which is a core part of the Precision Medicine and Diagnostics strategic area within the Data-Driven Life Science (DDLS) Program, funded by the Knut and Alice Wallenberg Foundation.

Impact

The research will directly inform clinical care by developing robust risk-stratification strategies and translating these tools into practice to guide personalized prevention and early‐detection programs. By uncovering novel molecular and epidemiological insights into pancreatic cancer initiation, progression, and metastasis, they aim to refine targeted screening and surveillance protocols. These advances will enable tailored treatment approaches, improving early diagnosis and therapeutic decision-making.

Ultimately, their work will strive to increase patient survival through precision screening and monitoring, while laying a data-driven foundation for future innovations in pancreatic cancer research and precision medicine.

| Research Output